Affiliation:
1. The affiliated Mental Health Center of Jiangnan University, Wuxi
Central Rehabilitation Hospital, Wuxi, Jiangsu, China
2. Genenexus Technology Corporation, Shanghai, China
Abstract
Abstract
Objective To determine if the cardiac function and “endocrinium” of
Chinese patients are associated with dopamine D2 (DRD2)
(rs6276) and DRD3 (rs6280, rs963468) genetic
polymorphisms when treated with amisulpride.
Methods This study enrolled 148 patients with schizophrenia who took
amisulpride orally for 8 weeks. DRD2 (rs6276) and DRD3 (rs6280,
rs963468) genetic polymorphisms were detected with TaqMan-MGB allelic
discrimination.
Results Analysis by multivariate covariance analysis (MANCOVA) showed that
after adjusting for age, gender, and the baseline level, the increase in the
level of aspartate aminotransferase (AST) and creatine kinase (CK) in the
rs6276 AG group was higher than that in the AA and GG groups.
Similarly, the changed estradiol (E2) level in rs6276 GG and
rs963468 GG groups was higher than that in the other two groups.
Adjusting for covariates, the increased triglyceride (TG) level in rs6276
GG and rs963468 GG groups was the highest among their different genotype
groups. The increase in the level of “AST” in the rs6280 TT group was
higher than that in the CC and CT groups upon adjusting for covariates.
Similarly, MANCOVA showed that the increase in the level of “CK” in the
rs6280 CT group was higher than that in the CC and CT groups.
Besides, the increased level of “PRL” in the rs6280 CC group and
rs963468 GG group was higher than that in their other two genotypes
groups.
Conclusion
DRD2 (rs6276) and DRD3 (rs6280,
rs963468) polymorphisms can affect amisulpride tolerability since they
are associated with the observed adverse reactions, including cardiac
dysfunction and endocrine disorders in Chinese patients with schizophrenia.
Reference26 articles.
1. Decreased cortical gyrification and surface area in the left medial parietal
cortex in patients with treatment-resistant and ultratreatment-resistant
schizophrenia;K Kazutoshi;Psychiatry Clin Neurosci,2023
2. Differences in inflammatory marker profiles and cognitive functioning between
deficit and nondeficit schizophrenia;W Dandan;Front Immunol,2022
3. Prioritization of potential causative genes for schizophrenia in the
placenta;U Gianluca;Nat Commun,2023
4. Amisulpride augmentation therapy improves cognitive performance and
psychopathology in clozapine-resistant treatment-refractory schizophrenia: A
12-week randomized, double-blind, placebo-controlled trial;H Z Ming;Mil Med Res,2022
5. The effectiveness and safety of amisulpride in Chinese patients with
schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm
study;Y Liang;Asia Pac Psychiatry,2016